Investment Rating - The report rates Connect Biopharma as a promising investment opportunity in the biopharmaceutical sector, particularly focusing on atopic dermatitis and asthma treatments [2]. Core Insights - Connect Biopharma has established a strong position in the biopharmaceutical industry through its innovative product pipeline and effective commercialization strategies, which have led to stable cash flow and enhanced market competitiveness [9][10]. - The company is well-positioned to capitalize on the growing demand for biologics in the treatment of autoimmune diseases, with a focus on self-immune markets along the Belt and Road Initiative [22][25]. Company Financial Performance - Connect Biopharma achieved a stable cash flow in 2023, with total cash and short-term investments decreasing to $120 million from $160 million in 2022 [10]. - The company's R&D expenditure was $51.9 million in 2023, down from $96.6 million in 2022, reflecting a strategic focus on cost management while maintaining innovation [10][12]. - The asset-liability ratio remains low at 6%-9%, significantly below the industry average of 30%-50%, indicating strong solvency and lower borrowing costs [14]. - The liquidity ratio is maintained above 10%, showcasing the company's robust short-term debt repayment capability [15]. - Revenue quality has improved, with a growth from 48.4% in 2021 to 104.5% in 2023, indicating a sustainable revenue outlook [16]. Business Layout - Connect Biopharma operates with a light asset model, avoiding heavy fixed asset burdens, which allows for a healthy cash flow state [18]. - The company has established a global presence with headquarters in California and a significant operational base in Suzhou, China, enhancing its market reach [19]. Product Pipeline - The core product pipeline includes CBP-201, targeting IL-4Ra for atopic dermatitis and asthma, and CBP-307, targeting S1P1 for ulcerative colitis and Crohn's disease, both showing significant clinical potential [20][21]. - CBP-201 has shown promising results in clinical trials, with plans for NDA submission in Q1 2024 [21][35]. Future Development Strategy - Connect Biopharma aims to enhance its R&D capabilities and expand its market share through strategic partnerships with pharmaceutical companies, focusing on autoimmune diseases [22][25]. - The company is exploring international markets, particularly in Southeast Asia and other Belt and Road countries, to leverage growth opportunities in the biopharmaceutical sector [22][27].

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024 SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company") ...

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract ...

Core Insights - Connect Biopharma announced that data from its global Phase 2b trial of rademikibart for moderate-to-severe asthma has been accepted for presentation at the ATS 2024 International Meeting [1] - The company focuses on developing therapies for chronic inflammatory diseases through T cell-driven research [1][3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases [3] - The company is developing innovative therapies, including rademikibart, which targets interleukin-4 receptor alpha (IL-4Rα) for treating atopic dermatitis and asthma [3] - Another product candidate, icanbelimod, is in development for ulcerative colitis [3] Presentation Details - The poster presentation titled "Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma" will be presented by Dr. Edward Kerwin [2] - The session is scheduled for May 22, 2024, at the San Diego Convention Center [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE A ...

Financial Performance - Connect Biopharma reported a net loss of $59.5 million for the year ended December 31, 2023, a significant decrease from a net loss of $118.1 million in 2022, representing a 49.7% reduction [14]. - Research and development expenses decreased to $51.9 million in 2023 from $96.6 million in 2022, a reduction of 46.3% primarily due to fewer clinical trials and lower personnel costs [13]. - Cash, cash equivalents, and short-term investments totaled $118.7 million as of December 31, 2023, down from $161.9 million in 2022, with a decrease of $43.2 million attributed to clinical program advancements [12]. - Total assets decreased to $125.9 million in 2023 from $174.0 million in 2022, while total liabilities increased to $24.8 million from $16.5 million [17]. - Administrative expenses were reduced to $14.5 million in 2023 from $20.8 million in 2022, a decrease of 30.5% due to lower professional fees and share-based compensation [13]. Clinical Trials and Programs - The rademikibart program demonstrated significant improvements in lung function in asthma patients, with results showing early improvement as soon as Week 1 and sustained effects through Week 24 [3]. - In the China pivotal trial for atopic dermatitis, approximately 90% of patients on a four-week dosing regimen maintained clinical response through Week 52 [4]. - Connect Biopharma has scheduled two meetings with the FDA in Q2 2024 to discuss registrational programs for rademikibart in atopic dermatitis and asthma [11]. - The company anticipates receiving updates from Simcere regarding the NDA filing for rademikibart in Q2 2024 [11]. Partnerships and Agreements - The company signed an exclusive licensing agreement with Simcere, receiving an upfront payment of ¥150 million ($21 million) and potential milestone payments of up to ¥875 million ($120 million) [10].

SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Financial Performance - Cash, cash equivalents, and short-term and long-term investments were RMB 1,127.3 million (USD 161.9 million) as of December 31, 2022, down from RMB 1,706.9 million (USD 267.7 million) at the end of 2021[7] - Net loss for the year ended December 31, 2022, was RMB 797.1 million (USD 114.4 million), a decrease from a net loss of RMB 1,306.8 million (USD 205.0 million) in 2021[9] - Total liabilities as of December 31, 2022, were RMB 115.1 million (USD 16.5 million), with total shareholders' equity at RMB 1,096.9 million (USD 157.5 million)[15] Research and Development - R&D expenses for the year ended December 31, 2022, totaled RMB 652.2 million (USD 93.6 million), an increase from RMB 518.0 million (USD 81.2 million) in 2021, primarily due to higher clinical trial costs[8] - The ongoing CBP-201 China pivotal trial in atopic dermatitis is expected to complete the 36-week stage 2 maintenance phase in the second half of 2023[4] - Positive topline data from Stage 1 of the ongoing CBP-201 China pivotal trial in atopic dermatitis was reported on a primary analysis population of 255 patients[3] - The Company anticipates reporting top-line results from the Phase 2 trial for CBP-201 in asthma in the second half of 2023[5] - Results from the Phase 2 maintenance portion of the CBP-307 trial in ulcerative colitis are expected to be reported in Q2 2023[6] Administrative Expenses - Administrative expenses increased to RMB 139.4 million (USD 20.0 million) for the year ended December 31, 2022, compared to RMB 122.4 million (USD 19.2 million) in 2021[9] Future Plans - The Company plans to submit a New Drug Application (NDA) for CBP-201 for atopic dermatitis by the end of Q1 2024, with potential regulatory approval in China as early as 2025[2]